142 related articles for article (PubMed ID: 35245727)
21. Molecular characterization of equine thymidine kinase 1 and preliminary evaluation of its suitability as a serum biomarker for equine lymphoma.
Wang L; Unger L; Sharif H; Eriksson S; Gerber V; Rönnberg H
BMC Mol Cell Biol; 2021 Dec; 22(1):59. PubMed ID: 34906077
[TBL] [Abstract][Full Text] [Related]
22. Feline thymidine kinase 1: molecular characterization and evaluation of its serum form as a diagnostic biomarker.
Wang L; Sharif H; Saellström S; Rönnberg H; Eriksson S
BMC Vet Res; 2021 Sep; 17(1):316. PubMed ID: 34579716
[TBL] [Abstract][Full Text] [Related]
23. X-irradiation effects on thymidine kinase (TK): I. TK1 and 2 in normal and malignant cells.
He Q; Skog S; Welander I; Tribukait B
Cell Prolif; 2002 Apr; 35(2):69-81. PubMed ID: 11952642
[TBL] [Abstract][Full Text] [Related]
24. Elevated serum thymidine kinase activity in canine splenic hemangiosarcoma*.
Thamm DH; Kamstock DA; Sharp CR; Johnson SI; Mazzaferro E; Herold LV; Barnes SM; Winkler K; Selting KA
Vet Comp Oncol; 2012 Dec; 10(4):292-302. PubMed ID: 22236280
[TBL] [Abstract][Full Text] [Related]
25. Monitoring plasma nucleosome concentrations to measure disease response and progression in dogs with hematopoietic malignancies.
Wilson-Robles H; Warry E; Miller T; Jarvis J; Matsushita M; Miller P; Herzog M; Turatsinze JV; Kelly TK; Butera ST; Michel G
PLoS One; 2023; 18(5):e0281796. PubMed ID: 37163491
[TBL] [Abstract][Full Text] [Related]
26. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
Wang Z; Zhang W; Huo B; Dong L; Zhang J
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a point-of-care test for canine C-reactive protein.
Plickert HD; Einspanier R; Arndt G; Brunnberg L; Kohn B
Vet Clin Pathol; 2011 Sep; 40(3):384-8. PubMed ID: 21827518
[TBL] [Abstract][Full Text] [Related]
28. Impact of serum C-reactive protein level as a biomarker of cancer dissemination in canine lymphoid neoplasia.
Manachai N; Umnuayyonvaree D; Punyathi P; Rungsipipat A; Rattanapinyopituk K
Vet World; 2022 Dec; 15(12):2810-2815. PubMed ID: 36718344
[TBL] [Abstract][Full Text] [Related]
29. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
He Q; Zhang P; Zou L; Li H; Wang X; Zhou S; Fornander T; Skog S
Oncol Rep; 2005 Oct; 14(4):1013-9. PubMed ID: 16142366
[TBL] [Abstract][Full Text] [Related]
30. Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma.
Mattsson Ulfstedt J; Venge P; Holmgren S; Enblad G; Eriksson S; Molin D
Ups J Med Sci; 2021; 126():. PubMed ID: 34471484
[TBL] [Abstract][Full Text] [Related]
31. Aptamer-Based Sandwich Assay for Measurement of Thymidine Kinase 1 in Serum of Cancerous Patients.
Nazari M; Gargari SLM; Sahebghadam Lotfi A; Rassaee MJ; Taheri RA
Biochemistry; 2019 May; 58(18):2373-2383. PubMed ID: 30900869
[TBL] [Abstract][Full Text] [Related]
32. Serum thymidine kinase 1 levels correlate with clinical characteristics of esophageal squamous cell carcinoma.
Ji Y; Wu XB; Chen JY; Hu B; Zhu QK; Zhu XF; Zheng MF
Int J Clin Exp Med; 2015; 8(8):12850-7. PubMed ID: 26550200
[TBL] [Abstract][Full Text] [Related]
33. Selection of human single domain antibodies (sdAb) against thymidine kinase 1 and their incorporation into sdAb-Fc antibody constructs for potential use in cancer therapy.
Velazquez EJ; Cress JD; Humpherys TB; Mortimer TO; Bellini DM; Skidmore JR; Smith KR; Robison RA; Weber SK; O'Neill KL
PLoS One; 2022; 17(3):e0264822. PubMed ID: 35239730
[TBL] [Abstract][Full Text] [Related]
34. Serum detection of thymidine kinase 1 as a means of early detection of lung cancer.
Alegre MM; Weyant MJ; Bennett DT; Yu JA; Ramsden MK; Elnaggar A; Robison RA; O'Neill KL
Anticancer Res; 2014 May; 34(5):2145-51. PubMed ID: 24778016
[TBL] [Abstract][Full Text] [Related]
35. Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer.
Tribukait B; Lundgren PO; Kjellman A; Norming U; Nyman CR; Jagarlmundi K; Gustafsson O
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982234
[TBL] [Abstract][Full Text] [Related]
36. Extracellular cyclic adenosine monophosphate-dependent protein kinase A autoantibody and C-reactive protein as serum biomarkers for diagnosis of cancer in dogs.
Ryu MO; Kim BG; Choi US; Baek KH; Song YK; Li Q; Seo KW; Ryeom S; Youn HY; Bhang DH
Vet Comp Oncol; 2019 Mar; 17(1):99-106. PubMed ID: 30411459
[TBL] [Abstract][Full Text] [Related]
37. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report.
Nisman B; Nechushtan H; Biran H; Gantz-Sorotsky H; Peled N; Gronowitz S; Peretz T
J Thorac Oncol; 2014 Oct; 9(10):1568-72. PubMed ID: 25521401
[TBL] [Abstract][Full Text] [Related]
38. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
39. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma.
He E; Xu XH; Guan H; Chen Y; Chen ZH; Pan ZL; Tang LL; Hu GZ; Li Y; Zhang M; Zhou J; Eriksson S; Fornander T; Skog S
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):352-8. PubMed ID: 20544519
[TBL] [Abstract][Full Text] [Related]
40. Serum C-reactive protein concentration as an indicator of remission status in dogs with multicentric lymphoma.
Nielsen L; Toft N; Eckersall PD; Mellor DJ; Morris JS
J Vet Intern Med; 2007; 21(6):1231-6. PubMed ID: 18196731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
